Position in INCY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,135,840
+$212,440 QoQ
Shares Held
12,068
+29.1% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INCY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CSS LLC/IL holds $14,889,923 across 15 Biotechnology names. INCY ranks #3 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
79,093 | $5,939,093 | |
| 2 | APLS |
Apellis Pharmaceuticals, Inc.
|
42,818 | $1,722,568 | |
| 3 | INCY |
Incyte Corp
This page
|
12,068 | $1,135,840 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,170 | $903,988 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
15,980 | $902,710 | |
| 6 | ACLX |
Arcellx, Inc.
|
7,600 | $872,632 | |
| 7 | EXEL |
Exelixis, Inc.
|
15,879 | $681,050 | |
| 8 | CNTA |
Centessa Pharmaceuticals plc
|
17,000 | $675,240 |
All Filings in INCY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,135,840 | 12,068 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $923,400 | 9,349 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $992,955 | 11,708 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $667,243 | 9,798 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $495,904 | 8,190 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $686,555 | 9,940 | Shares | Sole | 2025-02-18 | |
| 2023-09-30 | $361,120 | 6,251 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||